Top Clinical Trials companies in Japan by Net Cash Used Provided By Financing Activities
Japan
# |
Name |
Net Cash Used Provided By Financing Activities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 4.06 B
|
March 31, 2024 | USD 9.46 | 1.16% |
|
Japan |
|
| 2 |
USD 342.51 M
|
Dec. 31, 2023 | USD 6.35 | 2.58% |
|
Japan |
|
| 3 |
USD 75.73 M
|
Dec. 31, 2023 | USD 22.68 | 5.69% |
|
Japan |
|
| 4 |
USD 52.65 M
|
March 31, 2024 | USD 10.19 | 8.20% |
|
Japan |
|
| 5 |
USD 35.14 M
|
March 31, 2024 | USD 12.27 | 5.66% |
|
Japan |
|
| 6 |
USD 16.21 M
|
Jan. 31, 2024 | USD 5.34 | 6.29% |
|
Japan |
|
| 7 |
USD 8.38 M
|
Dec. 31, 2023 | USD 1.91 | 2.54% |
|
Japan |
|
| 8 |
USD 8.10 M
|
Dec. 31, 2023 | USD 3.66 | 1.69% |
|
Japan |
|
| 9 |
USD 5.62 M
|
Dec. 31, 2023 | USD 2.65 | 4.67% |
|
Japan |
|
| 10 |
USD 4.82 M
|
Dec. 31, 2023 | USD 1.21 | 0.22% |
|
Japan |
|
| 11 |
USD 4.44 M
|
March 31, 2024 | USD 0.17 | 4.80% |
|
Japan |
|
| 12 |
USD 3.59 M
|
March 31, 2024 | USD 1.65 | 22.29% |
|
Japan |
|
| 13 |
USD 1.95 M
|
Dec. 31, 2023 | USD 0.25 | 3.49% |
|
Japan |
|
| 14 |
USD 1.87 M
|
Dec. 31, 2023 | USD 13.30 | 2.22% |
|
Japan |
|
| 15 |
USD 1.08 M
|
March 31, 2024 | USD 18.44 | 0.77% |
|
Japan |
|
| 16 |
USD 24.63 K
|
March 31, 2024 | USD 0.93 | 0.77% |
|
Japan |
|
| 17 |
USD -1.62 M
|
March 31, 2024 | USD 2.10 | -1.79% |
|
Japan |
|
| 18 |
USD -1.62 M
|
June 30, 2024 | USD 1.00 | 0.77% |
|
Japan |
|
| 19 |
USD -3.03 M
|
Sept. 30, 2024 | USD 9.59 | 3.33% |
|
Japan |
|
| 20 |
USD -6.35 M
|
March 31, 2024 | USD 2.30 | 4.06% |
|
Japan |
|
| 21 |
USD -8.21 M
|
March 31, 2024 | USD 11.55 | 2.65% |
|
Japan |
|
| 22 |
USD -13.42 M
|
March 31, 2024 | USD 3.30 | 4.32% |
|
Japan |
|
| 23 |
USD -22.11 M
|
March 31, 2024 | USD 9.13 | -1.99% |
|
Japan |
|
| 24 |
USD -29.91 M
|
March 31, 2024 | USD 15.35 | 0.99% |
|
Japan |
|
| 25 |
USD -47.39 M
|
March 31, 2024 | USD 5.69 | -0.47% |
|
Japan |
|
| 26 |
USD -66.11 M
|
March 31, 2024 | USD 24.56 | 1.18% |
|
Japan |
|
| 27 |
USD -88.98 M
|
June 30, 2024 | USD 8.40 | 1.17% |
|
Japan |
|
| 28 |
USD -224.84 M
|
March 31, 2024 | USD 9.63 | -2.79% |
|
Japan |
|
| 29 |
USD -230.58 M
|
Dec. 31, 2023 | USD 14.79 | 0.14% |
|
Japan |
|
| 30 |
USD -838.12 M
|
March 31, 2024 | USD 14.57 | 3.59% |
|
Japan |
|
| 31 |
USD -987.44 M
|
Dec. 31, 2023 | USD 44.59 | 2.75% |
|
Japan |
|
| 32 |
USD -2.34 B
|
March 31, 2024 | USD 27.51 | 2.57% |
|
Japan |
Frequently Asked Questions
-
Which Clinical Trials company in Japan has the highest Net Cash Used Provided By Financing Activities ?
The Clinical Trials company in Japan with the highest Net Cash Used Provided By Financing Activities is Astellas Pharma Inc. (Tokyo Stock Exchange: 4503.T) at USD 4.06 B.
-
Which Clinical Trials company in Japan has the lowest Net Cash Used Provided By Financing Activities ?
The Clinical Trials company in Japan with the lowest Net Cash Used Provided By Financing Activities is Takeda Pharmaceutical Company Limited (Tokyo Stock Exchange: 4502.T) at USD -2.34 B.
-
What are the top 10 Clinical Trials companies in Japan by Net Cash Used Provided By Financing Activities ?
The top 10 Clinical Trials companies in Japan by Net Cash Used Provided By Financing Activities are Astellas Pharma Inc., Nxera Pharma Co., Ltd., GNI Group Ltd., Qol Holdings Co., Ltd., Shin Nippon Biomedical Laboratories, Ltd., SanBio Company Limited, Carna Biosciences, Inc., Oncolys BioPharma Inc., RaQualia Pharma Inc. and SymBio Pharmaceuticals Limited.
-
What are the bottom 10 Clinical Trials companies in Japan by Net Cash Used Provided By Financing Activities ?
The bottom 10 Clinical Trials companies in Japan by Net Cash Used Provided By Financing Activities are Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Kyowa Kirin Co., Ltd., Santen Pharmaceutical Co., Ltd., Macromill, Inc., Kissei Pharmaceutical Co., Ltd., Cytori Cell Research Institute, Inc., FALCO HOLDINGS Co., Ltd. and KYORIN Holdings, Inc..
